The science of RLT and Novartis RLT services

RLT is an innovative approach to cancer treatment that delivers targeted ionising radiation directly to tumour cells, wherever they are in the body.1,2

Designed for precision

 

RLT is a precision-medicine approach that recognises and directly treats a disease by using specific biomarkers expressed on the surface of target cells and delivering radiation with a cytotoxic effect.1,2

Using this approach, RLTs can be engineered to specifically target markers expressed in a variety of cancers, including prostate and neuroendocrine tumours.1,2

Image of scientists in a lab.

From production to patient – powered by manufacturing expertise

 

We source scarce materials years before they are required, activate them in highly regulated sterile environments, and transfer the radiopharmaceuticals from production to eligible patients.

Our vision for automated lines and expanded capacity will set benchmarks in the manufacturing of RLTs.

Image to represent manufacturing expertise.

Learn how we ensure every dose is delivered with precision from production to eligible patients

Discover our manufacturing and logistics process

Learn more about prostate cancer

Click here

Learn more about scanning for PSMA

Click here

Learn more about neuroendocrine tumours

Click here

DNA, deoxyribonucleic acid; PSMA, prostate-specific membrane antigen; RLI, radioligand imaging; RLT, radioligand therapy.

References

  1. George SJ & Samuel EJJ. Front Chem 2023;11:1218670.

  2. Sgouros G, et al. Nat Rev Drug Discov 2020;19(9):589–608.

  3. Duan H, et al. Nanotheranostics 2022;6(1):103–117.

  4. Yordanova A, et al. Onco Targets Ther 2017;10:4821–4828.

  5. Van der Heide CD & Dalm SU. Eur J Nucl Med Mol Imag 2022;49(13):4616–4641.

  6. Locametz®▼ (gozetotide) Summary of Product Characteristics.

  7. SomaKit TOC® (edotreotide) Summary of Product Characteristics.

UK | December 2025 | FA-11482672

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.